Evidence map›Paper›PMID 27683208›Full record

ArticleCancer medicine2016

The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.

Leila Khoja, Eshetu G Atenafu, Arnoud Templeton, Ye Qye, Mary Anne Chappell, Sam Saibil, David Hogg, Marcus O Butler, Anthony M Joshua

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 8 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 8 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. CD21Journal of personalized medicine · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Leila KhojaPrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Eshetu G AtenafuPrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Arnoud TempletonPrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Ye QyePrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Mary Anne ChappellPrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Sam SaibilPrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
David HoggPrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Marcus O ButlerPrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Anthony M JoshuaPrincess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada. anthony.joshua@uhn.ca.
Princess Margaret Cancer Centre · CAMelbourn Science Park · GBThe Kinghorn Cancer Centre · AU

Funding

CIHR
6 · The paper itself

Abstract

Ipilimumab produces durable responses in some metastatic melanoma patients. Neutrophil, platelet, and eosinophil to lymphocyte ratios (NLR, PLR, and ELR) may be associated with the immune response in cancer thereby acting as biomarkers of toxicity and efficacy in ipilimumab-treated patients. Data were collected on clinical characteristics and lactate dehydrogenase (LDH), NLR, PLR, and ELR at baseline, post cycle 2 and at the end of treatment for 183 patients treated with ipilimumab between 2008 and 2015 at the Princess Margaret Cancer Centre. Associations between clinical characteristics, LDH, NLR, PLR, and ELR with toxicity or survival outcomes of progression-free (PFS) and overall survival (OS) were assessed using univariable and multivariable analysis. Prognostic models of outcome at each time point were determined. Of the 183 patients included, the median age was 58, 85% had M1c disease, 58% were performance status 1, and 64% received ipilimumab as second line therapy. Median follow up was 7.5 months (range: 0.3-49.5), median PFS was 2.8 months (95% confidence intervals (CI): 2.8-3.2), and median OS was 9.6 months (95% CI: 7.9-13.2). Prognostic factors for OS by multivariable analysis were LDH and NLR at all-time points. Prognostic models using LDH (× 2 upper limit of normal) and NLR 4) differentiated patients into high, moderate, and low risk of death prior to or on ipilimumab treatment (P < 0.0001 for each model). No factors were associated with toxicity. Prognostic models based on NLR and LDH values at baseline and on treatment differentiate patients into good, intermediate, and poor prognostic groups and may be relevant in patient management.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorCutaneous Malignant MelanomaDisease-Free SurvivalFemaleHumansIpilimumabLeukocyte CountL-Lactate DehydrogenaseLymphocyte CountMaleMelanomaMiddle AgedAntineoplastic AgentsBiomarkers, TumorIpilimumabL-Lactate DehydrogenaseBiomarkerseosinophil to lymphocyte ratioimmune-related adverse eventsipilimumabmelanomaneutrophil to lymphocyte ratioplatelet to lymphocyte ratiotoxicity

Identifiers

PMID27683208
PMCPMC5083732
OpenAlexW2523880687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.